Relaxation drinks and their use in adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 6, 2011, Pages 605-610

  Stacy, Sylvie ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KAVA; MELATONIN; TRYPTOPHAN; VALERIAN;

ADOLESCENT; ALCOHOL CONSUMPTION; ARTICLE; BEVERAGE; COGNITION; HUMAN; RELAXATION DRINK; RELAXATION SENSATION; SEDATION; SLEEP QUALITY; STRESS;

ADOLESCENT; ADOLESCENT BEHAVIOR; BEVERAGES; DIETARY SUPPLEMENTS; HUMANS; MARKETING; NONPRESCRIPTION DRUGS; RELAXATION;

EID: 84555196278     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0026     Document Type: Article

References (46)

1. Andreatini R, Sartori VA, Seabra ML, Leite JR: Effect of valepotri-ates (valerian extract) in generalized anxiety disorder: A randomized placebo-controlled pilot study. Phytother Res 16:650-654, 2002. (Pubitemid 35334186)
2. Arendt J, Skene DJ: Melatonin as a chronobiotic. Sleep Med Rev 9:25-39, 2005. (Pubitemid 40092916)
3. Arria AM, Claire M: The "high" risk of energy drinks. JAMA 305:600-601, 2011.
4. Awad R, Muhammad A, Durst T, Trudeau VL, Arnason JT: Bioassay-guided fractionation of lemon balm using an in vitro measure of GABA transaminase activity. Phytother Res 23:1075-1081, 2009.
5. Blendon RJ, DesRoches CM, Benson JM, Brodie M, Altman DE: Americans' views on the use and regulation of dietary supplements. Arch Intern Med 161:805-810, 2001. (Pubitemid 32225388)
6. Boullata JI, Nace AM: Safety issues with herbal medicine. Pharma-cotherapy 20:257-269, 2000. (Pubitemid 30140744)
7. Bourin M, Bougerol T, Guitton B, Broutin E: A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: Controlled study versus placebo. Fundam Clin Pharmacol 11:127-132, 1997. (Pubitemid 27128116)
8. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I: Effects of exogenous melatonin on sleep: A meta-analysis. Sleep Med Rev 9:41-50, 2005. (Pubitemid 40092917)
9. Buck R, Davis WA: Marketing risk: Emotional appeals can promote the mindless acceptance of risk. Emotions and Risky Technologies. Int Lib Ethics Law 5:61-80, 2010.
10. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Har-tling L, Vohra S, Klassen TP, Baker G: Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis. BMJ 332:385-93, 2006.
11. Carman JS, Post RM, Buswell R, Goodwin FK: Negative effects of melatonin on depression. Am J Psychiatry 133:1181-1186, 1976.
12. Cerny AS, Schmid K: Tolerability and efficacy of valerian/lemon balm in healthy volunteers; a double-blind placebo-controlled, multicentre study. Fitoterapia 70:221-228, 1999. (Pubitemid 29377035)
13. Chan TY: An assessment of the delayed effects associated with valerian overdose. Int J Clin Pharmacol Ther 36:569, 1998. (Pubitemid 28468235)
14. Courtland E: Weed in a Bottle: Mary Jane's Relaxing Soda. Culvert City, CA: LA Weekly, 2009.
15. Dress H, Kohler S, Muller WE: Improvement in sleep quality with a high dose valerian-melissa preparation. Psychopharmakotherapie 3:123-130, 1996. (Pubitemid 26278240)
16. Escher M, Desmeules J, Giostra E, Mentha G: Hepatitis associated with kava, a herbal remedy for anxiety. BMJ 322:139, 2001. (Pubitemid 32116192)
17. Garges HP, Varia I, Dorasiswamy PM: Cardiac complications and delirium associated with valerian root withdrawal. JAMA 280:1566-1567, 1998. (Pubitemid 28520640)
18. Gershwin ME, Borchers AT, Keen CL, Hendler S, Hagie F, Greenwood MC: Public safety and dietary supplementation. Ann N Y Acad Sci 1190:104-117, 2010.
19. Howland J, Rohsenow DJ, Calise TV, MacKillop J, Metrik J: Caf-feinated alcoholic beverages: An emerging public health problem. Am J Prev Med 40:268-271, 2011.
20. Humberston CL, Akhtar J, Krenzelok EP: Acute hepatitis induced by kava-kava. J Toxicol Clin Toxicol 41:109-113, 2003.
21. Jussofie A, Schmiz A, Hiemke C: Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of the rat brain. Psychopharmacology 116:469-474, 1994. (Pubitemid 24374249)
22. Kalueff AV, Nutt DJ: Role of GABA in anxiety and depression. Depress Anxiety 24:495-517, 2006. (Pubitemid 350086263)
23. Kaminer Y: Problematic use of energy drinks by adolescents. Child Adolesc Psychiatr Clin N Am 19:643-650, 2010.
24. Kennedy DO, Wake G, Savelev S, Tildesley NT, Perry EK, Wesnes KA, Scholey AB: Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology 28:1871-1881, 2003. (Pubitemid 41070853)
25. Kennedy J, Wang C, Wu C: Patient disclosure about herb and supplement use among adults in the US. eCAM 5:451-456, 2008.
26. Leuschner J, Muller J, Rudmann M: Characterisation of the central nervous depressant activity of a commercially available valerian root extract. Arzneimittelforschung 43:638-641, 1993. (Pubitemid 23176485)
27. Lewy AJ, Emens JS, Sack RL, Hasler BP, Bernert RA: Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period. Chronobiol Int 19:649-658, 2002. (Pubitemid 34596531)
28. Lu K, Gray MA, Oliver C, Liley DT, Harrison BJ, Bartholomeusz CF, Phan KL, Nathan PJ: The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psycho-pharmacol 19:457-465, 2004. (Pubitemid 39378268)
29. Lude S, Torok M, Dieterle S, Jaggi R, Buter DB, Drahenbuhl S: Hepatocellular toxicity of kava leaf and root extracts. Phytomedi-cine 15:120-131, 2008. (Pubitemid 350297905)
30. MacGregor FB, Abernethy VE, Dahabra S, Cobden I, Hayes PC: Hepatotoxicity of herbal remedies. BMJ 299:1156-1157, 1989. (Pubitemid 19266434)
31. Martinez C: Alertness and Relaxation Drinks Market Passes US$500 Million. Bath, UK: Zenith International Ltd., 2011.
32. Meolie AL, Rosen C, Kristo D, Kohrman M, Gooneratne N, Aguillard RN, Fayle R, Troell R, Townsend D, Claman D, Hoban T, Mahowald M: Oral nonprescription treatment for insomnia: An evaluation of products with limited evidence. J Clin Sleep Med 1:173-187, 2005.
33. Michelson D, Page SW, Casey R, Trucksess MW, Love LA, Milstien S, Wilson C, Massaquoi SG, Crofford LJ, Hallett M: An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J Rheumatol 21:2261-2265, 1994.
34. Muller D, Pfeil T, von den Driesch V: Treating depression comorbid with anxiety-results of an open, practice-oriented study with St John's wort and valerian extract in high doses. Phytomedicine 10:25-30, 2003. (Pubitemid 36597153)
35. Pittler MH, Ernst E: Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis. J Clin Psychopharmacol 20:84-89, 2000. (Pubitemid 30056358)
36. Reisig CJ, Strain EC, Griffiths RR: Caffeinated energy drinks-a growing problem. Drug Alcohol Depend 11:1-10, 2009.
37. Rodriguez RR: Warning Letter. White Oak, MD: U.S. Food and Drug Administration, 2010.
38. Rogers PJ, Smith JE, Heatherley SV, Pleydell-Pearce CW: Time for tea: Mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Psycho-pharmacology 195:569-577, 2008. (Pubitemid 350160491)
39. Seiffge-Krenke I, Aunola K, Nurmi JE: Changes in stress perception and coping during adolescence: The role of situational and personal factors. Child Dev 80:259-279, 2009.
40. Smaldone A, Honig JC, Byrne MW: Sleepless in America: Inadequate sleep and relationships to health and well-being of our nation's children. Pediatrics 119:S29-S37, 2007. (Pubitemid 46397944)
41. Spinella M: The importance of pharmacological synergy in psychoactive herbal medicines. Altern Med Rev 7:130-137, 2002. (Pubitemid 34461524)
42. Stickel F, Baumuller HM, Seitz K, Vasilakis D, Seitz G, Seitz HK, Schuppan D: Hepatitis induced by kava. J Hepatol 39:62-67, 2003.
43. Storey M: The shifting beverage landscape. Physiol Behav 100:10-14, 2010.
44. Taibi DM, Landis CA, Petry H, Vitiella MV: A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 11:209-230, 2007. (Pubitemid 46756375)
45. U.S. Food and Drug Administration: Consumer Advisory: Kava-Containing Dietary Supplements may be Associated with Severe Liver Injury; White Oak, MD: U.S. FDA, 2002.
46. Weeks BS: Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action: Relarian™. Med Sci Monit 15:RA256-RA262, 2009.